Skip to main content
SpringerLink
Log in

Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Passamonti F (2012) Classification of myeloproliferative neoplasms and prognostic factors. Am Soc Clin Oncol Educ Book 32:419–424

    Google Scholar 

  2. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J et al (2009) The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33:1199–1203

    Article  PubMed  Google Scholar 

  3. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798

    Article  PubMed  CAS  Google Scholar 

  4. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF et al (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865–1871

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Kwasnicka H, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S (2013) Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica 98(Suppl 1), abstract S591

  6. Wilkins BS, Radia D, Woodley C, El Farhi S, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 98:1872–1876

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy

    Matteo Molica, Alessandra Serrao, Roberta Saracino, Irene Zacheo, Christof Stingone, Giuliana Alimena & Massimo Breccia

Authors
  1. Matteo Molica
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Serrao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberta Saracino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irene Zacheo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christof Stingone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuliana Alimena
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Massimo Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Breccia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Molica, M., Serrao, A., Saracino, R. et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?. Ann Hematol 93, 1951–1952 (2014). https://doi.org/10.1007/s00277-014-2096-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2096-y

Keywords

Search

Navigation